Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated With or Without Rituximab

Thrombosis and Haemostasis - Germany
doi 10.1055/s-0038-1668545
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Georg Thieme Verlag KG

Related search

Additional Autoimmune Disorders in Patients With Acquired Autoimmune Thrombotic Thrombocytopenic Purpura

American Journal of Hematology
Hematology
2019English

Acute Pancreatitis Preceding Thrombotic Thrombocytopenic Purpura

Haematologica
Hematology
2007English

Rituximab-Induced Acute and Delayed Serum Sickness in Thrombotic Thrombocytopenic Purpura: The Role of Anti-Rituximab Antibodies

British Journal of Haematology
Hematology
2018English

Relapsing or Refractory Idiopathic Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome: The Role of Rituximab

Transfusion
AllergyImmunologyHematology
2010English

Thrombotic Thrombocytopenic Purpura

American Journal of Medicine
Medicine
1959English

Thrombotic Thrombocytopenic Purpura

Laboratory Medicine
BiochemistryClinical Biochemistry
1988English

Acquired Thrombotic Thrombocytopenic Purpura

2020English

Thrombotic Thrombocytopenic Purpura: A Rare Complication of Acute Pancreatitis

JGH Open
HepatologyGastroenterology
2019English

Drug-Induced Thrombotic Thrombocytopenic Purpura Successfully Treated With Recombinant Human Soluble Thrombomodulin

Internal Medicine
Internal MedicineMedicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy